HOME >> BIOLOGY >> NEWS
Clinical study reports findings of combination therapy with DOXIL

h as improvement in disease-related symptoms or increased survival.

How DOXIL Works
DOXIL is an advanced form of doxorubicin, a liposomal formulation of doxorubicin, which means that doxorubicin is encapsulated by a fatty bilayer. The liposome is pegylated, which helps protect the drug from the immune system, resulting in the product circulating in the blood for a longer period of time. The longer circulation allows dosing once every four weeks.

Administration
DOXIL is administered intravenously in the doctor's office or clinic. Treatment usually takes from 30 minutes to one hour, though the first treatment may be longer.

  • To manage adverse events such as PPE, stomatitis, or hematologic toxicity, the dose may be delayed or reduced;
  • Pretreatment with or concomitant use of antiemetics should be considered; and
  • Limited clinical experience exists in treating hepatically impaired patients with DOXIL. Based on experience with doxorubicin HCl, it is recommended that DOXIL dosage be reduced if the bilirubin is elevated as follows: Serum bilirubin 1.2 to 3.0 mg/dL give normal dose, >3.0 mg/dL give normal dose.

Efficacy
DOXIL's refractory ovarian cancer indication was based on the results of three Phase II trials involving patients with metastatic ovarian cancer that was resistant to conventional chemotherapy. Most of the patients had been treated with two or more rounds of conventional chemotherapy, but the tumor was still progressing.

In these studies, patients with refractory metastatic ovarian cancer treated with DOXIL had a 13.8% (20/145) (95% CI 8.1% to 19.3%) combined response rate. The median time to response was 18 weeks, median duration of response was 39 weeks, and median time to disease progression was 16 weeks.

Warnings
In clinical trials, the most common side effects reported with DOXIL therapy included reduced red blood cel
'"/>


8-May-2003


Page: 1 2 3 4 5 6

Related biology news :

1. Creation of the UK Clinical Research Collaboration will boost clinical trials in UK
2. Clinical judgement still counts strongly alongside genetic testing
3. Jay Levy honored with 2004 Abbott Laboratories Award in Clinical and Diagnostic Immunology
4. Melvin Weinstein wins 2004 BD Award for Research in Clinical Microbiology
5. DFG to establish seven new Clinical Research Units
6. Clinical trial patients dont care about study sponsors or physician conflicts of interest
7. NIH establishes Rare Diseases Clinical Research Network
8. Clinical study results published in NEJM show promising data on Antegren (natalizumab)
9. Clinical trial shows timing of chemotherapy improves survival in breast cancer
10. Clinical services must catch up
11. Clinical Advances towards the simplification if HIV therapy: First once-daily dosing results for the HIV protease inhibitor, Agenerase

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Clinical study reports findings combination therapy with DOXIL

(Date:4/14/2015)... NEW YORK , April 14, 2015 /PRNewswire/ ... Fast IDentity Online (FIDO ® ) Alliance tm ... standards-based specifications. FIDO members commit to share technology ... authentication methods that are interoperable, more secure and ... specifications enable biometric identity verification that protects sensitive ...
(Date:4/13/2015)... , April 13, 2015 ... Research, "Global Biometrics Market Forecast & Opportunities, 2020", the ... CAGR of around 14% till 2020. The biometrics ... large scale implementation and review of biometric management ... of new products with greater efficiency, are resulting ...
(Date:4/10/2015)... , April 10, 2015 Research ... of the "Security Competitive Profiles - NEC" ... , NEC will continue to supply a ... the market, with a company focus on the development ... Winning opportunities in the Asia-Pacific ...
Breaking Biology News(10 mins):HYPR Corp. Joins the FIDO Alliance 2HYPR Corp. Joins the FIDO Alliance 3Global Biometrics Market to Cross US$ 21 Billion by 2020: TechSci Research 2NEC Security Competitive Profile 2015 2
(Date:4/23/2015)... Athena San Diego, an organization that accelerates ... San Diego’s technology and life science sectors, will announce ... their Gala on April 30, 2015 from 5-9pm at ... http://athenasd.org/events/ , The Pinnacle Awards recognize individuals and ... of fostering networking, risk taking and diversity of thought, ...
(Date:4/23/2015)... April 23, 2015 /CNW/ - A new and innovative ... from North America,s largest ... won Silver in the "Sustainability, service" category of ... Brandcheck "Competitor Comparison" is a service that scores ... and Global peers. This benchmarking process shows clients ...
(Date:4/23/2015)... D.C. (PRWEB) April 23, 2015 ... D.C. region on April 4-17 as part of ... marks the fourth group of biotechnology startups to ... of Nizhny Novgorod (UNN) and the University of ... deepen ties between their respective universities in the ...
(Date:4/23/2015)... -- WuXi PharmaTech (Cayman) Inc. (NYSE: WX ), ... serving the pharmaceutical, biotechnology and medical device industries, with ... the United States , today announced that ... of 2015 after the New York Stock Exchange closes ... morning, May 14, 2015 Shanghai time). The earnings release ...
Breaking Biology Technology:Athena Pinnacle Awards to Honor Executives, Corporations and Educators Working to Promote Women Leaders 2U.S.-Russian Innovation Corridor Program Connects Visiting Russian Startups to U.S. Experts 2U.S.-Russian Innovation Corridor Program Connects Visiting Russian Startups to U.S. Experts 3U.S.-Russian Innovation Corridor Program Connects Visiting Russian Startups to U.S. Experts 4WuXi PharmaTech Schedules First-Quarter 2015 Earnings Release 2WuXi PharmaTech Schedules First-Quarter 2015 Earnings Release 3
Cached News: